Edition:
United Kingdom

Aspen Pharmacare Holdings Ltd (APNJ.J)

APNJ.J on Johannesburg Stock Exchange

31,000.00ZAc
17 Nov 2017
Change (% chg)

-- (--)
Prev Close
31,000.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,061,919
52-wk High
32,750.00
52-wk Low
25,564.00

Chart for

About

Aspen Pharmacare Holdings Limited is a South Africa-based supplier and manufacturer of branded and generic pharmaceutical products, as well as infant nutritional and consumer healthcare products. The Company's segments include International, South Africa, Asia Pacific and Sub-Saharan Africa (SSA). Its International business... (more)

Overall

Beta: 0.56
Market Cap(Mil.): R139,674.20
Shares Outstanding(Mil.): 456.45
Dividend: 287.00
Yield (%): 0.94

Financials

  Industry Sector
P/E (TTM): -- 31.15 16.44
EPS (TTM): -- -- --
ROI: -- 14.99 10.62
ROE: -- 16.33 14.20

UK anti-trust regulator investigates South Africa's Aspen Pharmacare

JOHANNESBURG Britain's competition regulator has launched an investigation into Africa's biggest generic drug maker Aspen Pharmacare over alleged anticompetitive conduct in the supply of blood pressure and arthritis drugs, Aspen said on Friday.

13 Oct 2017

UK anti-trust regulator investigates South Africa's Aspen Pharmacare

JOHANNESBURG Britain's competition regulator has launched an investigation into Africa's biggest generic drug maker Aspen Pharmacare over alleged anticompetitive conduct in the supply of blood pressure and arthritis drugs, Aspen said on Friday.

13 Oct 2017

UK anti-trust regulator investigates S.Africa's Aspen Pharmacare

JOHANNESBURG, Oct 13 Britain's competition regulator has launched an investigation into Africa's biggest generic drug maker Aspen Pharmacare over alleged anticompetitive conduct in the supply of blood pressure and arthritis drugs, Aspen said on Friday.

13 Oct 2017

South Africa watchdog drops over-charging probe into Aspen, Equity

JOHANNESBURG South Africa's competition watchdog has dropped an investigation into Aspen Pharmacare and Equity Pharmaceutical, saying a case against them for over-charging for cancer medicines "cannot be sustained."

04 Oct 2017

UPDATE 1-S.Africa watchdog drops over-charging probe into Aspen, Equity

JOHANNESBURG, Oct 4 South Africa's competition watchdog has dropped an investigation into Aspen Pharmacare and Equity Pharmaceutical, saying a case against them for over-charging for cancer medicines "cannot be sustained."

04 Oct 2017

S.Africa watchdog drops over-charging probe into Aspen, Equity

JOHANNESBURG, Oct 4 South Africa's competition watchdog has dropped an investigation into Aspen Pharmacare and Equity Pharmaceutical, saying a case against them for over-charging for cancer medicines "cannot be sustained."

04 Oct 2017

BRIEF-Aspen Pharmacare Holdings ‍welcomes SA Competition Commission’s decision not to refer complaint about Aspen

* ‍WELCOMES SOUTH AFRICAN COMPETITION COMMISSION'S DECISION TO DROP ITS INVESTIGATION OF ASPEN FOR SUSPECTED ABUSE OF DOMINANCE AND EXCESSIVE PRICING Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

04 Oct 2017

UPDATE 2-Aspen Pharmacare shifts the needle to injectibles

JOHANNESBURG, Sept 14 South Africa's Aspen Pharmacare expanded its anaesthetic drugs portfolio with a $766 million deal with AstraZeneca as it focuses on injectibles rather than making tablets.

14 Sep 2017

South Africa's Aspen Pharmacare posts 46 pct profit jump

JOHANNESBURG, Sept 14 South Africa's Aspen Pharmacare reported a 46 percent rise in full-year profit, buoyed by a revenue boost from an anaesthetics portfolio acquired from AstraZeneca and GlaxoSmithKline, the company said on Thursday.

14 Sep 2017

BRIEF-Aspen Pharmacare Holdings posts FY revenue 41,2 bln rand

* RAISED NORMALISED HEADLINE EARNINGS PER SHARE ("NHEPS") BY 16% TO 1 463 CENTS IN YEAR ENDED 30 JUNE 2017.

14 Sep 2017

Earnings vs. Estimates